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Abstract
Background: Evidence based medicine depends on unbiased selection of completed randomized
controlled trials. For completeness it is important to publish all trials. This report describes the first
large randomised controlled trial where combination therapy was compared to placebo therapy
and to ribavirin monotherapy, which has not been published untill now.
Methods:  One hundred and twenty one patients with chronic hepatitis C and elevated
transaminases who did not respond to previous treatment with standard interferon monotherapy,
were included from 16 centers in Belgium, the Netherlands and Luxembourg between 1992 and
1996. Patient poor-response characteristics were: genotype 1 (69%), HCV RNA above 2 × 106
copies/ml (55%) and cirrhosis (38%). Patients were randomized to 6 months combination therapy
with interferon alpha-2b (3 MU tiw) and ribavirin (1000–1200 mg / day), 6 months ribavirin
monotherapy (1000–1200 mg / day) or 6 months ribavirin placebo. The study was double blinded
for the ribavirin / placebo component. One patient did not fit the entry criteria, and 3 did not start.
All 117 patients who received at least one dose of treatment were included in the intention to treat
analysis.
Results: At the end of treatment, HCV RNA was undetectable in 35% of patients on combination
therapy and in none of the patients treated with ribavirin monotherapy or placebo. The sustained
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virological response rate at 6 months after therapy was 15% for patients treated with interferon
and ribavirin.
During the 6 months treatment period 13% of patients on interferon ribavirin combination therapy,
13% of patients on ribavirin monotherapy and 11% of patients on placebo withdrew due to side
effects or noncompliance. At 24 weeks of treatment the mean Hb level was 85% of the baseline
value, which means a mean decrease from 9.1 mmol/l to 7.8 mmol/l. The Hb levels at the end of
treatment were not significantly different from patients treated with ribavirin monotherapy (p =
0.76). End of treatment WBC was significantly lower in patients treated with combination therapy,
compared to ribavirin (p < 0.01) as well as for patients treated with ribavirin monotherapy
compared to placebo (p < 0.01).
Discussion: This belated report on the only placebo controlled study of interferon ribavirin
combination therapy in non responders to standard doses of interferon monotherapy documents
the effectiveness, be it limited, of this approach as well as the dynamics of the effects on blood
counts.
Background
Until a decade ago, interferon was the only drug available
for the treatment of hepatitis C. Only a minority of
patients had a sustained response to standard doses of
interferon monotherapy. However, non-responders might
be still amendable to therapy by either high-dose daily
interferon [1] or by standard interferon in combination
with ribavirin [2]. This is a belated full report on the the
first and probably only RCT where combination therapy
was assessed in comparison to ribavirin monotherapy and
to placebo therapy.
Methods
Participants
Patients between 18 and 70 years of age with chronic hep-
atitis C, no ALT normalisation during and after treatment
and positive HCV RNA after treatment with interferon
monotherapy, were elegible for the study. The previous
treatment course consisted of three mega units interferon
thrice weekly for 24 weeks or at least eight weeks of treat-
ment with 6 mega units interferon thrice weekly or at least
4 weeks of 10 mega units interferon thrice weekly.
Patients with hepatitis of other viral origin, patients with
inherited metabolic liver disease, patients with acquired
metabolic liver disease related to alcohol, hepatotoxic
drugs or obesity and patients with autoimmune hepatitis
were excluded from the study. Other exclusion criteria
were significant medical illness within the past five years,
pregnancy or likelihood of becoming pregnant, immune
modulating therapy (corticosteroids) within the past 6
months, inadequate levels of hemoglobin (< 6 mmol/l),
platelet count (<50 × 10e9/l), white blood cells (< 3 ×
10e9/l), signs of hepatocellular carcinoma or decompen-
sated liver disease, recent drug or alcohol addiction and
unlikeliness to attend regularly for treatment and follow
up.
Data were collected in 16 centers in Belgium and in the
Netherlands; central data collection was done in the Eras-
mus Medical Center in Rotterdam, the Netherlands. The
study received ethics committee approval in all centers
involved and all patients gave signed informed consent.
Interventions
Patients were randomised and assigned to receive either
ribavirin (ICN pharmaceuticals, Bucks, United Kingdom)
monotherapy or a matched placebo orally twice a day in
a total dose of 1200 mg a day (body weight ≥ 75 kg) or
1000 mg a day (body weight <75 kg) for 24 weeks, or
interferon (Intron A, Schering Plough, Kenilworth, NJ,
USA) 3 mega units thrice a week combined with ribavirin
1000 or 1200 mg according to body weight during 24
weeks.
All patients were assessed in an outpatient setting for
safety, tolerance and efficacy at the end of weeks 2, 4, 8,
12, 16, 20 and 24 and every 4 weeks during follow up
until week 48. Initial HCV-RNA was measured by bDNA
with a lower detection limit of 2000 copies/ml, HCV-RNA
negativity at week 24 and week 48 was measured by PCR.
HCV-RNA and hematologic- and biochemical parameters
were measured in the certified laboratories of the partici-
pating hospitals; results were corrected for local normal
values. Liver biopsies, taken within 12 months before
treatment were reviewed by the local pathologist for the
presence or absence of cirrhosis.
Objectives
The objective of this study was to evaluate if interferon rib-
avirin combination therapy or ribavirin monotherapy
would be a therapeutic option for non-responders to pre-
vious interferon therapy.BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/24
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Outcomes
The primary endpoint for this study was defined as loss of
detectable serum HCV RNA 24 weeks after the end of
treatment. The secondary endpoint was normalisation of
alanine aminotransferase 24 weeks after treatment.
Sample size
It was calculated that 120 patients (40 per treatment arm)
were needed in order to have 90% chance of detecting a
difference of 30% at the significance level of p = 0.05 (sin-
gle sided testing) in disappearance of HCV RNA or nor-
malization of ALT levels, assuming the frequency of these
endpoints would be ten percent or less in the placebo
group.
Criteria for 50% dose reduction of ribavirin were anemia
with Hb < 5.4 mmol/l or excessive subjective symptoms
such as myalgia, fatigue or dyspepsia interfering severely
with daily activities. Criteria for a 50% dose reduction of
the total weekly interferon dose included leucopenia < 1.5
×10e9/l, thrombocytopenia < 40 ×10e9/l or excessive sub-
jective symptoms interfering with daily activities.
Randomization
Randomization was performed centrally at the coordina-
tion center in Rotterdam, the Netherlands after receiving
all entry data, by opening an envelope [3]. Patients were
randomized to either combination therapy or mono-
therapy at a ratio of 1:2 after stratification for the presence
of cirrhosis. The ribavirin and placebo arms were double
blinded. Patients allocated to monotherapy received
blinded study medication containing either ribavirin or
placebo.
Trial profile Figure 1
Trial profile. Patients who had a dose reduction following the protocol were included in all analyses.
120 patients enrolled
39 allocated to
placebo 24 weeks
41 allocated to ribavirin
1000-1200 mg 24 weeks
41 allocated to interferon a2b 3 
MU tiw + ribavirin 1000-1200 
mg 24 weeks
1 patient did not start                  
1 patient HCV RNA neg.
40 received treatment 40 received treatment 37 received treatment
3 dose reduction
4 interrupted
1 withdrawn
1 dose reduction
3 interrupted
2 withdrawn
2 interrupted
2 withdrawn
33 completed 24 weeks 
of treatment
35 completed 24 weeks 
of treatment
35 completed 24 weeks 
of treatment
Random
T=0
EOT
1 patient did not start 1 patient did not start
4 patients not
evaluable for
follow up
2 patients not
evaluable for
follow up
3 patients not
evaluable for
follow up
31 patients had treatment 
and follow up according 
to the protocol
33 patients had treatment
and follow up according 
to the protocol
30 patients had treatment
and follow up according 
to the protocol
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Allocation concealment
The randomization code of the monotherapy arms of the
study remained concealed until all patients had com-
pleted their follow up and the database had been verified
and closed.
Statistical analysis
All statistical analyses were peformed using SPSS for Win-
dows (Version 10 SPSS Inc, Chicago, IL, USA). The Kaplan
Meier method was used to evaluate the time of ALT nor-
malisation according to treatment using the log rank test
to assess statistical significance. The Pearson Chi-square
test was used to compare the differences in mean end of
treatment and end of follow up response between the dif-
ferent groups. The Mann Whitney test was used to com-
pare the differences in mean end of treatment blood
counts.
Results
Participant flow
121 patients were recruited from 16 university and affili-
ated hospitals in Belgium, the Netherlands and Luxem-
bourg ('Benelux'). Seventy seven patients had been treated
in a previous Benelux study on interferon mono therapy
[4], the other 44 had been treated with a comparable treat-
ment schedule of 6 MU interferon thrice a week for at least
12 weeks or 3 MU for at least 24 weeks.
One patient was excluded in view of a negative HCV RNA-
test at baseline and three never started therapy. All
Cumulative probability of ALT response during treatment Figure 2
Cumulative probability of ALT response during treatment. Intention to treat population, per treatment group. Response was 
defined as normal ALT on at least two sequential occasions, the time of response was taken at the first normal ALT. p = 0,00 
interferon + ribavirin vs placebo p = 0,02 ribavirin vs placebo p = 0,02 interferon + ribavirin vs ribavirin (Log rank test)
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remaining 117 patients were included in the analysis (fig
1).
Recruitment
Patients were recruited between 1992 and 1996.
Baseline data
There were no differences in patient characteristics
between the 3 treatment groups (table 1). Patient poor-
response characteristics were: genotype 1 (69%), HCV
RNA above 2 × 106 copies/ml (55%) and cirrhosis (38%).
Numbers analyzed
The results are presented on the basis of patients who
received at least one dosis of study medication, the inten-
tion to treat population. 40 patients received at least one
dose of combination therapy, another 40 patients
received at least one dose of ribavirin and 37 patients
received at least one dose of placebo.
Outcomes and estimation
Patients who received combination therapy had signifi-
cantly better responses than patients treated with ribavirin
monotherapy or placebo, both virologically (HCV-RNA
negativity) as well as biochemically (ALT normalisation).
At the end of treatment, HCV RNA was undetectable in
35% of patients on combination therapy and in none of
the patients treated with ribavirin monotherapy or pla-
cebo. The sustained virological response rate at 6 months
after therapy was 15% for patients treated with interferon
and ribavirin (table 2).
18% of patients receiving combination therapy, 3% of
patients receiving ribavirin monotherapy and 3% of
Changes in blood counts over time, by treatment Figure 3
Changes in blood counts over time, by treatment. A: hemoglobin; B: total white blood cells.
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patients receiving placebo treatment had persistently nor-
mal ALT levels during 24 weeks follow up (table 3).
Adverse events
Hemoglobin levels decreased in patients treated with
combination therapy and in patients treated with ribavi-
rin monotherapy (fig 3A). After week four a plateau-phase
was reached. There was a significant difference between
the end of treatment Hb change of the patients receiving
combination therapy or ribavirin monotherapy, com-
pared to patients treated with placebo (p < 0.01). The dif-
ference in mean end of treatment Hb change between
combination therapy and ribavirin monotherapy was not
statistically significant (p = 0.76).
Hemoglobin levels returned to baseline values for both
groups within 8 weeks after cessation of treatment. Pla-
cebo treatment did not significantly affect hemoglobin
levels.
White blood counts decreased in patients treated with
combination therapy with interferon and ribavirin (fig
3B). At week 12 the mean WBC for this group was 64%
from the baseline value. After week 12 a plateau-phase
was reached. Ribavirin monotherapy also caused a small,
but significant decrease in mean WBC. Placebo treatment
did not affect WBC levels.
The mean change in WBC at the end of treatment was
greater for the patients treated with combination therapy
Table 1: Base-line characteristics of the patients (intention-to-treat population).
Characteristic* Interferon and Ribavirin 6 mo (n = 40) Ribavirin 6 mo (n = 40) Placebo 6 mo (n = 37)
Age – yr 47 ± 12 48 ± 12 46 ± 12
Sex – M/F 28/12 28/12 31/6
Serum ALT – times ULN 3.8 ± 2.0 3.8 ± 2.0 3.7 ± 1.6
Serum HCV RNA†
Copies/ml – log10 6.2 ± 0.8 6.3 ± 0.8 6.3 ± 0.7
≥2 × 106 copies/ml – % 54 55 55
Genotype – n (%)
1 29 (79) 24 (62) 28 (76)
2 or 3 6 (16) 11 (22) 8 (23)
other 2 (5) 4 (6) 1 (3)
Cirrhosis – n (%) 18 (45) 13 (33) 14 (38)
*means ± SD. †Assessed by bDNA in 68 patients (24 interferon+ribavirin, 22 ribavirin, 22 placebo).
Table 2: HCV RNA response at end of therapy and end of follow up, by therapy.
HCV RNA negativity – n (%) Group A Interferon and Ribavirin 6 mo 
(n = 40)
Group B Ribavirin 6 mo (n = 40) Group C Placebo 6 mo (n = 37)
end of therapy 14 (35) 1 00
end of follow-up 6 (15) 2 00
1p < 0.01 (Pearson Chi-square) 2 p < 0.01 (Pearson Chi-square)
Table 3: ALT response, by therapy group
ALT response N (%) Group A Interferon and Ribavirin (n = 40) Group B Ribavirin (n = 40) Group C Placebo (n = 37)
On therapy1 23 (58%) 9 (23%) 3 (8.1%)
End of treatment2 19 (48%) 4 (10%) 2 (5.4%)
End of follow up3 7 (18%) 1 (2.7%) 1 (2.5%)
1normal ALT on at least two occasions with at least 1 month interval, p < 0.01 (Pearson Chi-square). 2normal ALT at week 24 and at least one 
month earlier, p < 0.01 (Pearson Chi-square). 3persistently normal ALT levels during 24 weeks follow up, p = 0.02 (Pearson Chi-square).BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/24
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than for patients treated with ribavirin monotherapy (p <
0.01). There was also a significant difference between the
end of treatment WBC change in patients receiving ribavi-
rin monotherapy compared to patients treated with pla-
cebo (p < 0.01).
Side effects
During the 6 months treatment period 13% of patients on
interferon ribavirin combination therapy, 13% of patients
on ribavrin monotherapy and 11% of patients on placebo
withdrew due to side effects or noncompliance (figure 1).
In the group receiving combination treatment 3 patients
needed dose reduction of interferon because of dyspnoea,
depression and pyelonephritis One patient stopped inter-
feron and had a dose reduction of ribavirin because of
subjective side effects and anemia.
Among patients treated with ribavirin, one had a dose
reduction because of anemia which gave rise to cardiovas-
cular complaints. One interrupted therapy because of
vasculitis.
Ancillary analyses
Figure 4 shows the rates of ALT normalisation of 26
patients who were treated in a previous trial with inter-
feron monotherapy [4] compared to the rates of ALT nor-
malisation the same patients showed in this trial on
combination therapy. There is a trend towards increased
ALT normalisation rate with interferon and ribavirin com-
bination therapy.
Discussion
In 1991 there were two main therapeutic options for
patients not responding to standard doses of interferon
monotherapy: treatment with high daily doses of inter-
feron [1] or combination therapy with interferon and
ribavirin.
Cumulative probability of ALT response during treatment Figure 4
Cumulative probability of ALT response during treatment. Patients treated with combination therapy in this trial vs results of 
the same patients in a previous trial with interferon monotherapy [4]. There is a trend towards increased normalisation rate 
with interferon and ribavirin combination therapy.
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To test this second option we started this randomised con-
trolled trial, in which we compared combination therapy
with interferon and ribavirin to ribavirin monotherapy
and to placebo. This trial is scientifically sound, with high
enough numbers treated to draw reliable conclusions. The
feasibility of such a trial was, however, low because of the
placebo arm included; consequently it took several years
for inclusion of all patients.
Part of the results of this study were published in meta-
analyses [5]. This full report can still be of value for meta-
analysis by the Cochrane approach and can serve as a ref-
erence for ribavirin monotherapy in non-responders and
for placebo therapy in non-responders.
This study documents a significant, though small effect of
adding ribavirin to the treatment of non-responders. Since
then various RCT have been published comparing combi-
nation therapy with interferon monotherapy [6–9].
Saracco et al. reported sustained response rates compara-
ble to the 15% we found in this study in patients asssigned
to a comparable treatment schedule [7]. In meta-analyses
that have been published on this subject, also response
rates of 14–16% have been reported [10–13]. One way to
increase response rates in patients retreated with combi-
nation therapy, is to make a stricter selection and to treat
only subgroups of patients who are more likely to have a
sustained response. Camma et al state that sustained
response rates can be increased to 30% by selecting
patients less than 45 years old with normal gam-
maglutamyltransferase levels and by treating them with
high dose long course combination therapy [12]. Indeed
Saracco et al have shown that non-responders benefit the
most from prolonged treatment with high dose
interferon, achieving response rates up to 23 % in these
patients.
In naive patients good results are obtained by treatment
with pegylated interferon combined with ribavirin
[14,15]. New studies are on their way evaluating the effect
of pegylated interferon and ribavirin in non-responders to
interferon.
This trial where combination treatment is compared to
ribavirin monotherapy and placebo therapy, gives us the
opportunity to determine which adverse effects can be
expected from which medication. The decrease in WBC in
combination therapy is mainly due to interferon, but also
ribavirin causes a modest, though significant decrease in
WBC.
The decrease in Hb levels seen during combination ther-
apy is almost entirely caused by ribavirin, with only a mar-
ginal additional effect of interferon.
Conclusion
This belated report on the only placebo controlled study
of interferon ribavirin combination therapy in non
responders to standard doses of interferon monotherapy
documents the effectiveness, be it limited, of this
approach as well as the dynamics of the effects on blood
counts.
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